Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MV NB 02

Next Previous
Drug Profile

MV NB 02

Alternative Names: GD2-GD3 Vaccine; MV Neuro; MV-NB-02; Neuroblastoma vaccine - MabVax/MSKCC

Latest Information Update: 29 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Y-mAbs Therapeutics
  • Class Cancer vaccines; Conjugate vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neuroblastoma

Most Recent Events

  • 08 Apr 2022 Updated efficacy and adverse events data from a phase II trial in Neuroblastoma presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
  • 31 Dec 2019 Memorial Sloan-Kettering Cancer Center has patent protection for MV NB02 vaccine in USA, before December 2019
  • 12 Dec 2019 Y-mAbs Therapeutics plans a multicenter phase II trial for Neuroblastoma in 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top